secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001628280-23-017392
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

COMPASS Pathways Q1 net loss $24.2M ($0.57/sh); Phase 3 psilocybin trials underway
--------------------------------------------------------------------------------

- Net loss $24.2M ($0.57 loss per share) vs $21.2M ($0.50) in Q1 2022.
- Cash $117.1M at March 31, 2023; raised additional $26.9M net via ATM in Q2.
- Phase 3 pivotal trials (COMP 005, COMP 006) in TRD underway; top-line data expected summer 2024 and mid-2025.
- CPT III code for psychedelic therapy support accepted by AMA, effective Jan 1, 2024.
- FY 2023 net cash used in operating activities guidance $85M-$110M; Q2 guidance $22M-$30M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000162828023017392/0001628280-23-017392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000162828023017392/cmps-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-017392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer